ImmuPharma (IMM) Competitors GBX 1.56 -0.03 (-1.89%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines IMM vs. AREC, SAR, OBI, OKYO, AOR, HEMO, RLM, NSCI, OPTI, and ONCShould you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Arecor Therapeutics (AREC), Sareum (SAR), Ondine Biomedical (OBI), OKYO Pharma (OKYO), AorTech International (AOR), Hemogenyx Pharmaceuticals (HEMO), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry. ImmuPharma vs. Arecor Therapeutics Sareum Ondine Biomedical OKYO Pharma AorTech International Hemogenyx Pharmaceuticals Realm Therapeutics NetScientific OptiBiotix Health Oncimmune Arecor Therapeutics (LON:AREC) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment. Which has more risk and volatility, AREC or IMM? Arecor Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Do analysts prefer AREC or IMM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arecor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AImmuPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders and institutionals have more ownership in AREC or IMM? 44.1% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 17.4% of ImmuPharma shares are owned by institutional investors. 25.3% of Arecor Therapeutics shares are owned by insiders. Comparatively, 48.3% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer AREC or IMM? In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score. Company Overall Sentiment Arecor Therapeutics Neutral ImmuPharma Neutral Which has preferable valuation & earnings, AREC or IMM? ImmuPharma has lower revenue, but higher earnings than Arecor Therapeutics. Arecor Therapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArecor Therapeutics£4.90M5.78-£8.67M-£0.28-267.86ImmuPharma£94.82K68.40-£2.46M-£0.01-155.75 Is AREC or IMM more profitable? ImmuPharma has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. Arecor Therapeutics' return on equity of -94.76% beat ImmuPharma's return on equity.Company Net Margins Return on Equity Return on Assets Arecor Therapeutics-176.89% -94.76% -37.31% ImmuPharma N/A -111.20%-43.00% Does the MarketBeat Community favor AREC or IMM? ImmuPharma received 266 more outperform votes than Arecor Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformArecor TherapeuticsN/AN/AImmuPharmaOutperform Votes26676.44% Underperform Votes8223.56% SummaryImmuPharma beats Arecor Therapeutics on 8 of the 12 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMM vs. The Competition Export to ExcelMetricImmuPharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.49M£158.40M£5.40B£1.63BDividend Yield0.77%3.39%5.16%11.03%P/E Ratio-155.75348.23113.091,785.79Price / Sales68.4019,806.471,478.84237,189.75Price / Cash20.5011.3039.8336.67Price / Book1.567.514.642.88Net Income-£2.46M-£18.90M£119.13M£148.87M7 Day Performance-8.65%-0.05%0.78%0.11%1 Month Performance-14.23%2.54%5.66%-0.11%1 Year Performance-8.49%28.85%36.92%15.75% ImmuPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMImmuPharmaN/AGBX 1.56-1.9%N/A-6.4%£6.49M£94,819.00-155.7513Gap DownARECArecor TherapeuticsN/AGBX 75+1.4%N/A-59.5%£28.32M£4.90M-267.8610Gap UpSARSareumN/AGBX 24.02-0.8%N/A-59.2%£25.93M£47,204.00-400.333,211Positive NewsGap DownOBIOndine BiomedicalN/AGBX 9+2.3%N/A-23.4%£24.96M£1.63M-300.00N/ANews CoverageGap UpOKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007Gap DownAORAorTech InternationalN/AGBX 123.50-2.4%N/AN/A£19.99M£539,000.00-33.383HEMOHemogenyx PharmaceuticalsN/AGBX 1.45-2.7%N/A-30.8%£19.43MN/A-145.0014Gap DownRLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/A+2.9%£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 11.80-9.2%N/A-68.2%£11.56M£1.26M-393.331News CoverageGap DownONCOncimmuneN/AGBX 14.79-1.4%N/A-4.3%£10.97M£1.21M-493.0052News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies AREC Alternatives SAR Alternatives OBI Alternatives OKYO Alternatives AOR Alternatives HEMO Alternatives RLM Alternatives NSCI Alternatives OPTI Alternatives ONC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:IMM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
